anastrozole


Also found in: Dictionary, Wikipedia.
Related to anastrozole: tamoxifen

anastrozole

 [ah-nas´trah-zōl″]
an aromatase inhibitor used for treatment of advanced breast carcinoma in postmenopausal women; it inhibits conversion of circulating androgens into estrogens.

anastrozole

Arimidex

Pharmacologic class: Nonsteroidal aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D

Action

Reduces serum estradiol levels with no significant effect on adrenocorticoid or aldosterone level; decreases stimulating effect of estrogen on tumor growth

Availability

Tablets: 1 mg

Indications and dosages

Postmenopausal women with hormone receptor-unknown or hormone receptor-positive advanced breast cancer or with advanced breast cancer after tamoxifen therapy; adjuvant treatment for hormone receptor-positive breast cancer

Adults: 1 mg P.O. daily

Contraindications

• Hypersensitivity to drug or its components
• Women of childbearing age

Precautions

Use cautiously in:
• ischemic heart disease
• breastfeeding patients
• children (safety and efficacy not established).

Administration

• Verify that patient isn't pregnant before giving drug.

Adverse reactions

CNS: headache, weakness, dizziness, depression, paresthesia, lethargy

CV: chest pain, peripheral edema, vasodilation, hypertension, thromboembolic disease

EENT: pharyngitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, anorexia, dry mouth

GU: vaginal bleeding, leukorrhea, vaginal dryness, pelvic pain

Musculoskeletal: decreased bone mineral density, fractures, bone or back pain, muscle weakness

Respiratory: dyspnea, cough

Skin: rash

Other: food distaste, weight gain, swelling, hot flashes, flulike symptoms, tumor flare hypersensitivity reactions (including anaphylaxis, angioedema, urticaria)

Interactions

Drug-diagnostic tests.Hepatic enzymes, low-density lipoproteins, total cholesterol: increased levels

Patient monitoring

Monitor patient closely for hypersensitivity reactions.
• Check regularly for signs and symptoms of thromboembolic disease, especially dyspnea and chest pain.
• Monitor for circulatory overload (suggested by peripheral edema, cough, and dyspnea).
• Assess for signs and symptoms of depression. Evaluate patient for suicidal ideation.
• Monitor liver function test results.

Patient teaching

Instruct patient to immediately notify prescriber if signs and symptoms of hypersensitivity occur (such as itching or swelling of face, lips, or throat).

Advise patient to immediately report signs and symptoms of thromboembolic disease and circulatory overload.
• Emphasize importance of preventing pregnancy during therapy.
• Tell patient to contact prescriber if she develops signs or symptoms of depression.
• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.
• Advise patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.
• Inform patient that she'll undergo regular blood testing during therapy.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

anastrozole

/anas·tro·zole/ (ah-nas´trah-zōl″) an antineoplastic used for treatment of advanced breast carcinoma in postmenopausal women.

anastrozole

a nonsteroidal aromatase inhibitor.
indication It is prescribed in the treatment of advanced breast cancer for postmenopausal women whose disease has not responded to treatment with tamoxifen.
contraindication The drug is usually effective only in patients with estrogen-dependent tumors.
adverse effects The side effects most often reported include diarrhea, fatigue, nausea, headache, hot flashes, and back pain.

anastrozole

An aromatase inhibitor, which converts androstenedione to estradiol in peripheral fat.
 
Indications
Postmenopausal women with advanced oestrogen-dependent breast cancer that does not respond to tamoxifen; unlike tamoxifen, anastrozole is not associated with increased risk of endometrial cancer.

anastrozole

An anti-oestrogen drug. Anastrozole is an aromatase-inhibitor anti-estrogen drug used in the treatment of advanced breast cancer in post-menopausal women. An aromatase is an enzyme that promotes the conversion of testosterone to the aromatic compound oestradiol (estradiol). This process occurs in women, and its inhibition can reduce oestrogen levels which can be helpful in the control of oestrogen-dependent tumours. The side effects may include any of those due to oestrogen deficiency. A brand name is Arimidex.
References in periodicals archive ?
Ten rabbits were placed in control group A and 10 placed in group B and were given anastrozole orally in the normal dose.
This FALCON trial was designed on the basis of positive results from the Phase II FIRST trial, which demonstrated a median overall survival nearly six months longer with Faslodex compared to anastrozole.
In the FALCON trial, median progression-free survival (PFS) was significantly longer with Faslodex than with the aromatase inhibitor, anastrozole - 16.
Investigators of two large randomized trials of anastrozole versus clomiphene reported that clomiphene was superior to anastrozole for induction of ovulation in the first cycle of treatment.
Travis Tygart, the head of the United States Anti-Doping Agency, clarified that there is can be no ambiguity on the usage of either Anastrozole or Clomephine which are both prohibited at any time.
After an average follow-up of five years, those who took anastrozole were 53 percent less likely to develop breast cancer than those who took the placebo (in all, 40 women in the anastrozole group developed breast cancer compared with 85 women in the placebo group).
The study looked at almost 4,000 postmenopausal women at high risk of breast cancer with half being given 1mg of anastrozole daily and half given a placebo.
Half of the men received the aromatase inhibitor anastrozole in addition, which created estradiol deficiency.
We present a case of recurrent and treatment refractory GCT in a postmenopausal patient, managed by aromatase inhibitor Anastrozole with reasonable efficacy.
Michael Baum, a well-known innovative breast surgeon, then at the Royal Marsden Hospital in London (who had performed the first adjuvant tamoxifen trial), with close colleagues decided to compare tamoxifen with anastrozole and with both drugs together in a three arm trial that we called ATAC (Arimadex, Tamoxifen Alone or in Combination).
We funded clinical trials that proved the benefit of drugs such as tamoxifen and Anastrozole.
All of the participants had received the aromatase inhibitors letrozole or anastrozole, nearly half had received tamoxifen, and two-thirds had received chemotherapy.